Pebish Jakke Gennemsigtig alectinib overall survival Fakultet erosion Sommerhus
Kaplan-Meier estimates of progression-free survival (PFS) in the... | Download Scientific Diagram
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study — ALK POSITIVE
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - ScienceDirect
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer☆ - ESMO Open
A) Kaplan-Meier curve of progression-free survival (PFS) in the... | Download Scientific Diagram
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer | SpringerLink
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Frontiers | Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
Kaplan-Meier curve for overall survival after total follow-up of ALK+... | Download Scientific Diagram
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer - ScienceDirect
Safety and effectiveness of alectinib in a real‐world surveillance study in patients with ALK‐positive non–small‐cell lung cancer in Japan - Masuda - 2019 - Cancer Science - Wiley Online Library
Charu Aggarwal, MD, MPH on Twitter: "Final OS analysis of J-ALEX Alectinib vs Crizotinib ✴️ No significant OS difference BUT ✴️ Majority of patients crossed over to alectinib (~78%) @ALKLungCancer @alk_fusion @ASCO #
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung
First-Line PFS - ALECENSA® (alectinib)
Stephen V Liu, MD on Twitter: "#ESMOAsia22 Survival is favoring alectinib for #ALK NSCLC over crizotinib, but not yet significant. Medians not reached and OS HR 0.60 overall with OS HR 0.40
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program | Oncotarget
Natural History and Factors Associated with Overall Survival in Stage IV ALK‐Rearranged Non–Small Cell Lung Cancer | Semantic Scholar
Diagnostics | Free Full-Text | Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
First-Line PFS - ALECENSA® (alectinib)
Cancers | Free Full-Text | Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
Potent treatment options in ALK– and MET-positive disease - memoinOncology